Penumbra Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.5B+26.0% YoYTTM through 30 Jun 2026
Net Income $160.6M+1,046.1% YoYTTM through 30 Jun 2026
Free Cash Flow $215.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 67.1% |
| EBITDA Margin | 13.6% |
| Operating Margin | 13.5% |
| Net Margin | 10.7% |
Returns
12.5%ROE
9.7%ROA
11.9%ROIC
Balance Sheet Health
Debt / Equity0.02x
Current Ratio6.64x
Net Debt-$521.7Mnet cash position
Cash & Equivalents$205.3M
Quality Metrics
Altman Z-Score18.97
Piotroski F-Score6 / 9
FCF Margin14.3%
Rule of 4020.2
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $1.4B
Diluted EPS$4.07TTMFY2025: $4.52
Dividend
No dividend
Capital Allocation
Capex Intensity4.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Thrombectomy | $947.9M | +16.2% | View detailsExpected to remain a primary growth driver under Boston Scientific's planned integration. |
| Embolization and Access | $455.7M | +20.2% | View detailsStrong momentum driven by product launches such as the Excel system. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.